Explore how diet impacts vitiligo, including foods to eat and avoid to support skin health and potentially slow ...

Recent network meta-analyses identified the relative outcomes of various vitiligo monotherapies on vitiligo at 6 months.

On March 17, China Medical System Holdings Limited (“CMS” or the “Company”) released its 2024 annual results. The Company recorded a turnover of RMB7,469 million, representing a year-on-year decrease ...

DAR ES SALAAM: THE Cuban Ambassador to Tanzania, Yordenis Vera, has emphasised that strong bilateral cooperation in the ...

Newly released data from the phase 3 STOP-HS clinical trial program reveal positive results in hidradenitis suppurativa from ...

STRATA Skin Sciences (SSKN) announces the results of a newly published study in Japan that further validates the technological advantages of ...

Caring Brands filed for an initial public offering to trade on Nasdaq. The cosmetics retailer said Thursday it will offer 750,000 shares at $4 each in the IPO. It plans to trade under the symbol CABR.

New drug candidate povorcitinib is a selective JAK1 inhibitor, given as a once-daily oral dose, which is intended to treat patients with more extensive forms of non-segmental vitiligo - the most ...

Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.

Under the terms of the deal, Sanofi will pay $600 million upfront to buy an affiliate of the California-based biotech, called ...

With the right strategy, reaching LPI ahead of schedule isn’t a myth. Learn how some biotech and pharma teams are achieving ...